Balaxi Pharmaceuticals Ltd

As of November 17, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 13.68, an EV to EBIT of 10.81, and a Price to Book Value of 0.83, making it a compelling investment opportunity despite a year-to-date stock decline of 50.32%.

As of 17-Nov, Balaxi Pharmaceuticals Ltd's stock price has declined to Rs. 35.92, marking a 4.03% drop and a new 52-week low. The company faces significant financial challenges, including a 53.75% negative return over the past year and reduced institutional interest, contributing to a lack of investor confidence.

As of November 12, 2025, Balaxi Pharma is considered undervalued with a PE ratio of 14.43, significantly lower than peers like Bajaj Finance and Bajaj Finserv, and has underperformed against the Sensex with a year-to-date return of -47.57%.

Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.

Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.

As of 12-Nov, Balaxi Pharmaceuticals Ltd's stock price is Rs. 37.91, down 5.15%, marking a new 52-week low and significant underperformance compared to its sector and the broader market. Despite a surge in delivery volume, negative sentiment and a year-to-date decline of 47.57% indicate waning investor confidence.

Balaxi Pharma's latest results are concerning, with a 27.40% year-on-year decline in net sales and a 95.42% drop in net profit, indicating significant operational challenges and cash management issues. The company is facing deteriorating profitability and efficiency, marking a troubling trend in its financial performance.

As of 11-Nov, Balaxi Pharmaceuticals Ltd's stock price is Rs. 39.97, down 4.19%, and has reached a 52-week low. The stock has significantly underperformed the market, with a year-to-date decline of 44.72% and a lack of positive developments contributing to weak investor sentiment.

As of 08-Oct, Balaxi Pharmaceuticals Ltd's stock price is Rs 42.69, down 2.11%, and trading near its 52-week low. The stock has significantly underperformed its sector and the broader market, with a year-to-date decline of 40.96%, indicating weak investor sentiment despite increased trading volume.

As of 24-Sep, Balaxi Pharmaceuticals Ltd is priced at 44.96, with a year-to-date decline of -37.82% and a one-year return of -58.94%. Despite strong long-term fundamentals, the stock has consistently underperformed against the Sensex and shows bearish trends, indicating a lack of confidence in its future prospects.

As of 23-Sep, Balaxi Pharmaceuticals Ltd's stock price is declining at 44.84, down 4.62%, and has underperformed its sector significantly. The company faces a 37.99% year-to-date decline in stock value and a sharp drop in profits, leading to reduced institutional investment and ongoing challenges in the market.

As of 22-Sep, Balaxi Pharmaceuticals Ltd is currently priced at 47.01, reflecting a 0.51% increase, but has a year-to-date decline of 34.99%. Despite short-term outperformance against the Sensex, the stock struggles with long-term performance issues.

As of 19-Sep, Balaxi Pharmaceuticals Ltd is priced at 46.77, having increased by 1.59% today. Despite short-term outperformance against the Sensex, the stock has a concerning long-term trajectory with a 57.25% decline over the past year and significant profit drops, indicating ongoing investor skepticism.

As of 18-Sep, Balaxi Pharmaceuticals Ltd is priced at 46.04, down 0.35%, and has underperformed its sector today. Despite a modest weekly gain, the stock has declined significantly over the past month and year, with recent negative financial results contributing to ongoing challenges.

As of 17-Sep, Balaxi Pharmaceuticals Ltd is priced at 46.20, showing a slight increase but underperforming against its sector and benchmarks with a year-to-date return of -36.11%. Despite strong long-term fundamentals, the company faces significant challenges due to a dramatic decline in profits and reduced institutional investor participation, indicating a challenging outlook.

As of 16-Sep, Balaxi Pharmaceuticals Ltd is priced at 46.05, up 1.68%, but has underperformed its sector and benchmarks, with a year-to-date return of -36.32% and a significant decline in profits. Despite strong fundamentals, reduced institutional interest and consistent underperformance indicate a challenging outlook for the stock.